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Background. The loss of renal function in chronic kidney
disease (CKD) patients leads to a variety of metabolic dis-
turbances that promote the development of secondary hyper-
parathyroidism (SH) and bone disease. One of these alterations,
hyperphosphatemia, is a persistent problem in patients with
CKD and is an important factor in the development and sever-
ity of SH as well as coronary artery and cardiac valve calcifica-
tion. To help control serum phosphorus (P), phosphate binders
are used to minimize intestinal absorption of P in these pa-
tients. Since the use of aluminum- and calcium-based phosphate
binders can result in severe side effects, other phosphate binders
have been proposed. One of these is lanthanum (La) carbonate.
Methods. Since there is some controversy as to the degree La
is absorbed by the intestine, whether it is deposited in tissues,
and what effect its prolonged use would have in patients with
chronic renal failure, we studied normal and uremic rats fed a
control diet or a diet with La carbonate (1.5% elemental La)
for 45, 90, or 110 days.
Results. As expected, plasma creatinine increased after the
induction of uremia and continued to increase with time. At 45
and 90 days, dietary La produced a reduction in plasma P in
normal rats (N + La) [45 days: 3.15 ± 0.35 vs. normal control
(NC) 4.41 ± 0.15 mg/dL, P < 0.01; 90 days: 3.20 ± 0.30 vs.
4.09 ± 0.15 mg/dL, P < 0.05], but not at 110 days. Plasma P was
initially lower (45 days) in both groups of La-treated rats (U +
La: 3.47 ± 0.28 vs. UC: 4.91 ± 0.27 mg/dL, P < 0.01), but was not
at 90 and 110 days. Whole blood La content was not increased
in rats fed the La diet and is, therefore, not a good indicator
of the La content of tissue. La was increased in kidney, femur,
and especially liver in normal and uremic rats fed the La diet.
Uremia markedly enhanced tissue accumulation of La (liver,
110 days: N + La: 849 ± 152 vs. U + La: 2676 ± 479 ng/g wet wt,
P < 0.01), which increased in a time-dependent manner. The
increase in La in the liver of normal rats was 44-fold compared
to control and 98-fold in the liver of uremic rats compared to
uremic control.
Conclusion. La accumulates in tissues, most strikingly in the
liver, and renal failure accelerates the accumulation. While this
Key words: lanthanum, phosphate binder, vascular calcification, renal
failure, phosphorus, secondary hyperparathyroidism.
Received for publication May 20, 2005
and in revised form June 22, 2005
Accepted for publication July 7, 2005
C© 2005 by the International Society of Nephrology
was a relatively short-term study, La accumulation increased
in a time-dependent manner. The effect of long-term La treat-
ment on patients with chronic renal insufficiency needs to be
evaluated.
The loss of renal function in chronic kidney disease
(CKD) patients leads to a variety of metabolic distur-
bances. These include alterations in mineral metabolism
and disturbances in parathyroid hormone (PTH) and vi-
tamin D metabolism that can lead to bone disease and
secondary hyperparathyroidism (SH) [1–2]. One of these
alterations, hyperphosphatemia, is a persistent problem
in patients with CKD and is an important factor in the
development and severity of SH. [3–5] In addition, dial-
ysis patients have a higher incidence of coronary artery
and cardiac valve calcification compared to the general
population, and cardiovascular disease accounts for more
than 50% of deaths among persons with end-stage renal
disease [6, 7]. In CKD patients, vascular calcification is
associated with elevated levels of serum phosphorus (P),
calcium (Ca), and the calcium-phosphorus product (Ca ×
P) [8–10]. Thus, the control of serum P in these patients
is imperative and is accomplished chiefly by dietary P
restriction and the use of oral phosphate binders, which
keep ingested P from being absorbed. The most common
phosphate binders have been aluminum- or Ca-based.
The use of aluminum-based phosphate binders has been
severely curtailed due to the severe side effects they pro-
duce on brain and bone [11–13]. After the discovery of
the detrimental effects of aluminum, Ca-based phosphate
binders became widely used. These are very effective in
binding P, but their use can lead to hypercalcemia, an in-
creased Ca × P product, and a higher incidence of arterial
calcification [14], especially in patients receiving vitamin
D therapy for the control of SH. Because of this, other
types of phosphate binders that do not contain aluminum
or Ca are being evaluated. Sevelamer hydrochloride is
increasingly being used [15, 16]. This phosphate binder
is very effective, is Ca- and metal-free, and is associated
with an improved lipid profile [17, 18]. Another proposed
phosphate-binder is a rare earth metal–based phosphate
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binder, lanthanum (La) carbonate [19–20]. While La car-
bonate appears to be effective, there is some controversy
as to the extent that La is absorbed, whether it is de-
posited in tissues, and what effect its prolonged use may
have in patients with chronic renal failure. Early studies
on metals and tissue toxicity showed that at high doses, La
can displace and replace Ca2+, blocking some Ca trans-
port in smooth muscle cells [21]. La interacts with bio-
logical membranes and can affect membrane-associated
enzymes and neuromuscular function [21]. In addition,
La, injected at high doses in the form of lanthanum chlo-
ride, was shown to specifically affect the morphology and
ultrastructure of the liver [21, 22]. More recent stud-
ies demonstrate that lanthanum carbonate, when given
orally, accumulates predominately in liver and show that
uremia enhances this accumulation [23, 24].
In the present study, La accumulation in various tissues
was evaluated in normal and uremic rats fed control diets
or diets containing 3% La carbonate (1.5% elemental
La).
METHODS
Effect of lanthanum
All studies were approved by the Washington Uni-
versity Animal Studies Committee in accordance with
federal regulations. Renal insufficiency was induced by
5/6 nephrectomy in a group of female Sprague-Dawley
rats (Harlan, Madison, WI, USA) weighing 225 to
250g. Briefly, this procedure involves ligation of most
of the branches of the left renal artery followed by
the ligation and removal of the right kidney. During
the study, the rats were fed powdered normal rodent
chow containing 0.98% Ca and 0.66% P (Harlan-Teklad
7012C) with either 3% lanthanum carbonate hydrate
(La2(CO3)3.8H2O) (1.5% elemental La) (Alfa Aesar,
Ward Hill, MA, USA) or 3% cellulose (Sigma-Aldrich,
St. Louis, MO, USA). Two groups of normal sham-
operated rats were fed the same 2 diets. Rats were killed
by exsanguination at day 45, day 90, or day 110. Blood was
taken for determination of plasma creatinine, phospho-
rus, and ionized calcium. Samples of whole blood, liver,
kidney, and femur were taken for determination of tis-
sue lanthanum content. Prior to analysis, tissues samples
were kept at −70◦C.
Tissue analysis
Tissues were degraded in 17.5% nitric acid followed
by microwave digestion in a Mars 5 microwave diges-
tion apparatus (CEM, Matthews, NC, USA). Solutions
were analyzed via Varian Vista MPX Radial ICP-OES
(Varian, Inc., Palo Alto, CA, USA) with emission inten-
sity at 408.671 nm to measure La.
Analytical determinations
Total calcium was determined by atomic absorp-
tion spectrophotometry (Model 1100B; Perkin-Elmer,
Norwalk, CT, USA), and ionized calcium was measured
using a Nova 8 electrolyte analyzer (Nova Biomedical,
Waltham, MA, USA). Plasma creatinine and phospho-
rus were determined by autoanalyzer (COBAS MIRA
Plus, Branchburg, NJ, USA).
Statistical analysis
All data are expressed as mean ± SEM. One-way anal-
ysis of variance (ANOVA) with the Tukey’s posttest was
used for comparison between groups at each time point.
Student nonpaired t test was used to compare time points
within each group and Student paired t test was used to
compare pre- and postmatched data within a group.
RESULTS
Normal and uremic rats were fed either a control diet or
a diet containing 3% La carbonate for 45, 90, or 110 days.
Plasma chemistries were evaluated as well as La accumu-
lation in whole blood, kidney, femur, and kidney.
At 45 days the average weight of the uremic rats re-
ceiving La was slightly lower than the uremic rats not
receiving La (UC: 274.9 ± 3.2 vs. U + La: 259.25 ± 4.38).
At later time points this was not the case (90 days: UC:
271.4 ± 4.8 vs. U + La: 260.69 ± 7.3 and 110 days: UC:
263.9 ± 6.3 vs. U + La: 263.9 ± 6.9).
Table 1 shows the serum chemistries in the 4 groups
of rats. As expected, serum creatinine was significantly
increased in all uremic animals and was further increased
at later time points. At 45 and 90 days, dietary La pro-
duced a reduction in plasma phosphorus in normal rats
receiving La (N + La) compared to normal control rats
(NC) (45 days: 3.15 ± 0.35 vs. 4.41 ± 0.15 mg/dL, P <
0.01; 90 days: 3.20 ± 0.30 vs. 4.09 ± 0.15 mg/dL, P < 0.05).
Plasma P was not significantly different, however, in the
2 normal groups at day 110 (N + La: 3.51 ± 0.68 vs. NC:
3.92 ± 0.65 mg/dL). In uremic animals, plasma phospho-
rus was significantly lower in La-treated rats (U + La)
compared to uremic control rats (UC) only at 45 days
(U + La: 3.47 ± 0.28 vs. UC: 4.91 ± 0.27 mg/dL, P <
0.01), but not at 90 days (U + La: 4.16 ± 0.56 vs. UC:
5.67 ± 0.63 mg/dL) or 110 days (U + La: 5.13 ± 0.45
vs. UC: 4.56 ± 0.14 mg/dL). At 45 days, ionized calcium
was slightly increased in the uremic group receiving La
(U + La) compared to the uremic control group (U + La:
4.80 ± 0.04 vs. UC: 4.69 ± 0.04 mg/dL, P < 0.05). Ionized
calcium was not different at later time points among any
of the groups.
The La content of whole blood was virtually unde-
tectable in all rats (data not shown). La was shown
to accumulate in kidney, femur, and liver. The kidney
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Table 1. Serum chemistries in control and lanthanum-treated rats
Chemistry Group N 45 days N 90 days N 110 days
ICa mg/dL NC 9 4.69 ± 0.05 6 4.71 ± 0.08 4 4.74 ± 0.03
N + La 10 4.74 ± 0.03 6 4.84 ± 0.06 5 4.82 ± 0.08
UC 12 4.69 ± 0.02 9 4.78 ± 0.06 6 4.69 ± 0.08
U + La 12 4.80 ± 0.04a 9 4.68 ± 0.06 12 4.83 ± 0.06
P mg/dL NC 9 4.41 ± 0.15 6 4.09 ± 0.15 4 3.92 ± 0.65
N + La 10 3.15 ± 0.35c 6 3.20 ± 0.30c 5 3.51 ± 0.68
UC 12 4.91 ± 0.27 9 5.67 ± 0.63 6 4.56 ± 0.14
U + La 12 3.47 ± 0.28b 9 4.16 ± 0.56 12 5.13 ± 0.45
Cr mg/dL NC 9 0.71 ± 0.04 6 0.78 ± 0.03 4 0.98 ± 0.03
N + La 10 0.78 ± 0.02 6 0.85 ± 0.03 5 0.86 ± 0.02
UC 12 1.25 ± 0.04d 9 1.97 ± 0.25d 6 1.60 ± 0.15c
U + La 12 1.30 ± 0.07d 9 1.96 ± 0.25d 12 1.86 ± 0.10d
Data are expressed as mean ± SEM.
aP < 0.05 from UC, bP < 0.01 from UC, cP < 0.05 from NC, dP < 0.01 from NC.
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Fig. 1. La content of kidneys from normal and uremic rats fed a 3%
lanthanum carbonate diet (1.5% elemental La). La accumulates in the
kidney and uremia enhances La deposition. Normal control (), normal
+ La (), uremic control (), uremic + La (). ∗P < 0.05 from UC, ∗∗P <
0.01 from UC, aP < 0.05 from NC, and w P < 0.01 from NC. Data are
expressed as mean ± SEM.
displayed very little background La (Fig. 1). In both the
N + La and U + La groups, La accumulation in the kid-
ney was increased compared to control animals. Uremia
enhanced La accumulation, which was higher at every
time point (45 days: N + La: 69 ± 10 vs. U + La: 132 ±
37 ng/g wet wt; 90 days: N + La: 65 ± 4 vs. U + La:103 ±
21 ng/g wet wt; 110 days: N + La: 116 ± 14 vs. U + La:
174 ± 37 ng/g wet wt).
More La accumulation was also seen in the femurs of
La-treated rats and increased with time (Fig. 2). Again,
uremia enhanced La accumulation (45 days: N + La:
307 ± 39 vs. U + La: 336 ± 28 ng/g wet wt; 90 days: N +
La: 300 ± 33 vs. U + La: 564 ± 61 ng/g wet wt, P < 0.01;
110 days: N + La: 438 ± 21 vs. U + La: 669 ± 130 ng/g
wet wt).
Figure 3 shows the La content of liver in the 4 groups of
animals over the course of the study. Of the tissues stud-
ied, the liver took up La most aggressively. While back-
ground La in the livers of normal and uremic control rats
was low and did not differ between the 2 control groups,
La content increased markedly in all La-treated rats. As
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Fig. 2. La content of femurs from normal and uremic rats fed a 3%
lanthanum carbonate diet (1.5% elemental La). La accumulates in the
femur and uremia enhances La deposition. Normal control (), normal
+ La (), uremic control (), uremic + La (). ∗∗P < 0.01 from UC,
aP < 0.05 from NC, w P < 0.01 from NC, and dP < 0.01 from N + La.
Data are expressed as mean ± SEM.
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Fig. 3. La content of liver from normal and uremic rats fed a 3% lan-
thanum carbonate diet (1.5% elemental La). La accumulates in the liver
and uremia enhances La deposition. Normal control (), normal + La
(), uremic control (), uremic + La (). ∗∗P < 0.01 from UC, w P <
0.01 from NC, and cP < 0.01 from N + La. Data are expressed as mean
± SEM.
in kidney and bone, renal failure significantly enhanced
the accumulation of La. This enhanced accumulation was
seen at all 3 time points (45 days: N + La: 538 ± 50 vs. U +
La: 1213±122 ng/g wet weight (wt), P <0.01; 90 days: N+
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Fig. 4. Comparison of the tissue content of La between normal and
uremic rats fed a diet with 3% La carbonate (1.5% elemental La) for
110 days. Uremia enhanced accumulation of La in kidney, femur, and
liver. La accumulation was most pronounced in the liver. cP < 0.05 vs.
normal + La. Data are expressed as mean ± SEM.
La: 696 ± 46 vs. U + La: 2143 ± 341 ng/g wet wt, P < 0.05;
110 days: N + La: 849 ± 152 vs. U + La: 2676 ± 479 ng/g
wet wt, P < 0.05) and steadily and consistently increased
with time. The La content of the livers of normal rats fed
La carbonate increased 43.7 ± 8.0-fold compared to con-
trol rats, while the fold increase in La content of liver in
uremic rats was 98.1 ± 17.7. In addition, the average daily
deposition rate of La did not change during the course of
the study (0–45 days = 27 ng/g wet wt/day, 45–90 days
= 21 ng/g wet wt/day, and 90–110 days = 27 ng/g wet
wt/day). Light and electron microscopy were performed
on sections of liver from rats at 110 days. In this short-term
study, however, we did not detect any histologic abnor-
malities in the liver (data not shown). In this particular
study longer time points were not possible due to the an-
imal mortality from renal failure. However, lanthanum
continued to accumulate in the liver at a steady rate dur-
ing the course of the study.
Figure 4 compares La accumulation in kidney, bone,
and liver in La-treated normal and uremic rats at the
end of the study (110 days). Again, these data emphasize
that La is taken up to a much greater extent by the liver
and that uremia markedly enhances the uptake of La by
these 3 tissues. Compared to normal La-treated rats, tis-
sue accumulation of La in uremia was 1.5 times greater
in kidney and bone and 3.2 times (P < 0.05) greater in
liver.
DISCUSSION
Lanthanum carbonate has been proposed as a phos-
phate binder. While it appears to be an effective
phosphate-binding agent, there is uncertainty about how
much is absorbed under uremic conditions, how much
accumulates in tissues, and what the long-term conse-
quences of this accumulation are. Results from studies
in normal subjects show minimal absorption and accu-
mulation of La [25], while recent studies suggest that the
uremic condition enhances the tissue accumulation of La
[23, 24]. The present studies also show that lanthanum,
when administered orally at a therapeutic dose in the
form of lanthanum carbonate, is absorbed by normal rats
and accumulates in tissue, especially the liver. This accu-
mulation increases over time and is markedly enhanced
in CKD.
In the current study, 3% La carbonate (1.5% elemen-
tal La) was used because this dose has been found to be
effective, at least in the short term, at binding phosphate
in rats fed the recommended amount of dietary phos-
phorus. While, at 45 days, lanthanum carbonate lowered
serum phosphorus in uremic rats receiving lanthanum,
it failed to do so at later time points. As renal disease
progressed (90 and 110 days), it is likely that the renal
excretion of phosphorus declined, and since we did not
further increase the dose of lanthanum, potentially 1.5%
of elemental lanthanum may not have been sufficient to
affect serum phosphorus.
While the concern with Al-based phosphate binders
centered around adverse effects of Al deposition on bone
and brain, La may have little effect on either tissue [26].
While some accumulation is seen in bone, La seems to
be taken up primarily by the liver. The long-term effect
of La deposition in the liver is not known, but prolonged
exposure of liver to other metals such as iron, copper,
and possibly cadmium are associated with liver toxicity
[27–30], cirrhosis [27–29], and hepatocellular [27, 30] car-
cinoma. The current studies encompass a period of less
than 3 months (110 days), but demonstrate a 100-fold in-
crease in La accumulation in liver in uremic rats fed a La
carbonate diet compared to their control counterparts. In
addition, La deposition in liver during the course of the
study did not level off but La continued to accumulate at
the same rate throughout the course of the study, suggest-
ing poor clearance of the metal once it enters the tissue.
In addition, blood levels of La in these animals are low
to undetectable, suggesting that the level of La in blood
is not a good indicator of La accumulation.
It has been speculated that patients with CKD are not
at risk of increased tissue accumulation of La since re-
nal elimination of La in normal subjects is miniscule. Our
current study, however, indicates the opposite, that CKD
markedly enhances La accumulation in tissues. Others
have reported similar results [23, 24]. In addition, Lacour
et al also found that urinary excretion of La was almost
15 times greater in 5/6 nephrectomized rats fed a diet
with 3% lanthanum carbonate compared to their normal
counterparts [23]. This would point to an increase in in-
testinal absorption of La in CRF rats. La would not be the
first metal whose absorption was shown to be increased in
CRF. Enhanced gastrointestinal absorption of aluminum
has also been documented in uremic patients [31].
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CONCLUSION
La accumulates in tissues, especially the liver, and CKD
markedly enhances La deposition. At present, it is diffi-
cult to project how long-term treatment with La might
affect patients with CKD. More information is clearly
needed to define the safety of La administration to a pop-
ulation of patients at risk for increased La absorption and
accumulation who will be treated chronically for months
or years.
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